Xifeng Wu, M.D., Ph.D.
Present Title & Affiliation
The overarching goal of my translational research program is to construct comprehensive, clinically applicable risk prediction models along the entire cancer continuum, from etiology to screening, prognosis, treatment response and survivorship. To accomplish the program’s objectives, my laboratory practices multidisciplinary research that bridges the fields of basic science, epidemiology, biostatistics, and clinical research. We devise integrative strategies that enable risk assessment, early detection and delineation of early- and late-stage clinical outcomes. Our investigations channel towards identification and validation of clinically useful prognostic and predictive biomarkers, and discovery of molecular targets with therapeutic potential. Assimilation of biomarkers with epidemiological, clinical, phenotypic, and genetic information enables development of accurate and reliable personalized cancer risk prediction models that inform clinical care and empower clinical risk stratification along the cancer care continuum. Our multifaceted and highly innovative research has yielded novel and signifcant findings across malignancies, including in bladder cancer, lung cancer, renal cell carcinoma, and gastrointestinal cancer.
We conduct and lead a number of high-profile initiatives that yield significant institutional-wide impact. The Center for Translational and Public Health Genomics is establishing a unique and prospective Cancer Patient Cohort comprised of all newly-presenting patients at MD Anderson. The cohort is specifically designed to enable address of determinants impacting cancer symptoms, prognosis, progression, treatment response, toxicity, survival, and quality of life. The cohort infrastructure encompasses an all-inclusive biorepository, the Blood Specimen Research Resource, which is seamlessly linked to the Patient History Database (PHDB). The electronic PHDB supports epidemiologic information related to core risks and exposures, and integrates all data with other institutional patient data resources.
My group engages in a number of major collaborative efforts. The Premalignant Genome Atlas program, conducted in concert with the Duncan Family Institute, assesses the full spectrum of risk factors contributing to initiation and progression of precancerous lesions. On another front, my collaboration with MJ Health facilitates both comprehensive and prospective analysis of risk factors associated with cancer and other diseases by query of the large MJ Cohort, a unique patient database established in association with a major health screening program conducted in Taiwan. At the institutional level, my group is heavily involved in multiple SPORE projects focusing on different cancer sites.
We successfully execute contemporary epidemiologic strategies across the cancer continuum by employing advanced, state-of-the-art technologies including high- and mid-throughput assay platforms for genotyping, whole-genome expression profiling, copy number analysis, next-generation sequencing, mitochondrial DNA analysis, and metabolome profiling.
- Established and led a large, multi-disciplinary, research team that includes data collection, biospecimen processing, , molecular and genomics lab, and statistical analysis
- Has a stellar record of extramural funding from NCI and CPRIT; published over 300 peer-reviewed papers, invited articles, and editorial articles.
- Extensive intra- and inter-institutional and international collaborations: co-PI of the Head and Neck SPORE, project leader in 4 SPOREs (lung, bladder, prostate, and head and neck) and 1 P01, and Chair of the International Consortium of Bladder Cancer
- Established the largest ongoing case control studies in the U.S. for bladder, esophageal, and renal cancer and one of the largest clinical outcome studies for lung cancer.
- Published seminal papers on identifying genetic susceptibility loci for cancer risk and survival
- Established: Center for Translational and Public Health Genomics; institutional Blood Specimen Research Resource, a biorepository for residual blood samples of all newly diagnosed patients; biorepository for long-term cancer patient survivors; and propelled implementation of electronic Patient History Database; Co-leader of the Premalignant Genome Atlas program in the Duncan Family Institute for Cancer Prevention and Risk Assessment
- Scientific director for a large prospective health screening cohort, MJ Cohort in Taiwan
- Genetic basis of cancer and interactions with environment, diet, and physical activitiy
- Integrative risk prediction models for cancer development, prognosis, and treament response
- Premalignant lesions: risk and progression to cancer
1155 Herman P. Pressler Blvd.
Unit Number: 1340
Houston, TX 77030
Room Number: CPB4.3301
Phone: (713) 745-2485
Fax: (713) 792-4657
Education & Training
|1994||The University of Texas Health Science Center at Houston School of Public Health, Houston, TX, PHD, Epidemiology|
|1984||Fudan University, Shanghai, China, MD, Medicine|
|1990-1991||Postdoctoral Fellowship, National Laboratory of Industrial Environment and Risk Analysis (INERIS), Verneuil-en-Halatte, France|
|2007||MD Anderson Cancer Center, Faculty Leadership Academy|
|6/2005||Center for Creative Leadership Training, Women's Leadership Program|
|1994||National Cytogenetic Specialist Certification|
Institutional Committee Activities
Honors and Awards
|2012||Wall of Science Publication Gallery Inclusion, The University of Texas MD Anderson Cancer Center|
|2011||Robert M. Chamberlain Distinguished Mentor Award, The University of Texas MD Anderson Cancer Center|
|2008-present||Betty B. Marcus Chair in Cancer Prevention, MD Anderson Cancer Center|
|2008-2013||Senior Fellow of the MD Anderson Research Trust, The University of Texas MD Anderson Cancer Center|
|2008||Julie and Ben Rogers Award for Excellence, The University of Texas MD Anderson Cancer Center|
|2008||The Margaret and James A. Elkins, Jr. Faculty Achievement Award in Cancer Prevention, The University of Texas MD Anderson Cancer Center|
|2006-2008||Ashbel Smith Professorship, The University of Texas|
|2002||Faculty Scholar Award, The University of Texas MD Anderson Cancer Center|
|1995||Richard C. Devereaux Award for Outstanding Young Investigators in Lung Cancer Prevention, Research Foundation of America|
|1993||D. Jack Kilian Scholarship|
|1989||Zhejiang Scientific and Technologic Award|
Grant & Contract Support
|Title:||Genetic Epidemiology of non-Hodgkin Lymphoma|
|Funding Source:||Mayo Clinic - NIH/NCI|
|Principal Investigator:||James Cerhan|
|Duration:||7/1/2016 - 6/30/2021|
|Title:||MD Anderson Cancer Patient and Survivor Cohort (MDA-CPSC)|
|Funding Source:||Apache Corporation|
|Duration:||9/1/2014 - 8/31/2020|
Last updated: 12/21/2016